Clinical Trials for Tislelizumab

Find clinical trials for tislelizumab. Discover research opportunities and treatment options in your area.

12 Active Trials Found

Showing 12 trials on this page

Page 1 of 1

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

NCT ID: NCT07136077

This clinical trial is testing whether a combination of two medicines, fruquintinib and tislelizumab, can help control colorectal cancer in patients who have finished their initial chemotherapy but...

Not yet recruiting

Phase: PHASE2 Type: interventional Locations: Houston, Texas, United States

Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer

NCT ID: NCT07125547

This clinical trial is studying a new treatment approach for patients with ureteral cancer, which is a type of cancer in the tube that connects the kidney to the bladder. The trial is testing wheth...

Recruiting

Phase: PHASE2 Type: interventional Locations: Tianjin, Tianjin, China

Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer

NCT ID: NCT07086456

This clinical trial is studying a new combination treatment for people with a specific type of lung cancer called locally advanced non-small cell lung cancer (NSCLC) that cannot be removed by surge...

Recruiting

Phase: PHASE2 Type: interventional Locations: Guangzhou, China

Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer(TitAN) : A Prospective, Single-Arm, Phase II Study

NCT ID: NCT07089199

This clinical trial is studying a new combination treatment given before surgery for people with stage III non-small cell lung cancer (NSCLC) that can be removed by surgery. The treatment combines ...

Not yet recruiting

Phase: PHASE2 Type: interventional

Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study

NCT ID: NCT07085182

This clinical trial is studying a new treatment approach for people with advanced non-squamous non-small cell lung cancer, a type of lung cancer that has spread beyond the lungs (stage IIIB, IIIC, ...

Recruiting

Phase: PHASE2 Type: interventional Locations: Zibo, Shandong, China

Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Advanced Pulmonary Pleomorphic Carcinoma

NCT ID: NCT05375734

This clinical trial is studying a combination of two treatments, tislelizumab and anlotinib, for patients with advanced pulmonary pleomorphic carcinoma, a type of lung cancer that is difficult to t...

Recruiting

Phase: PHASE2 Type: interventional Locations: Nanchang, Jiangxi, China

Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer

NCT ID: NCT06871527

This clinical trial is investigating a new treatment approach for adults with advanced gastric (stomach) cancer or gastroesophageal junction (GEJ) adenocarcinoma. The study aims to see how safe and...

Not yet recruiting

Phase: PHASE1 Type: interventional Locations: Guangzhou, Guangdong, China

Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors

NCT ID: NCT05920863

This clinical trial is exploring a new treatment approach for patients with early-stage liver cancer, specifically those at high risk of their cancer coming back after surgery. The treatment combin...

Recruiting

Phase: PHASE2 Type: interventional Locations: Hangzhou, Zhejiang, China

Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis

NCT ID: NCT06233981

This clinical trial is investigating a new treatment approach for patients with hepatocellular carcinoma (HCC), a type of liver cancer, who also have tumor thrombosis, meaning that the cancer has s...

Recruiting

Phase: PHASE2 Type: interventional Locations: Beijing, China

Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer

NCT ID: NCT06134193

This clinical trial is exploring a new treatment approach for patients with biliary tract cancer that cannot be surgically removed or has spread to other parts of the body. Specifically, the study ...

Not yet recruiting

Phase: PHASE2 Type: interventional

XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

NCT ID: NCT05970302

This clinical trial is studying a new treatment combination for patients with a specific type of advanced colorectal cancer known as metastatic colorectal adenocarcinoma that has certain genetic mu...

Recruiting

Phase: PHASE2 Type: interventional Locations: Beijing, China

Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer

NCT ID: NCT05841134

This clinical trial is studying a new treatment approach for patients with stage II or III colorectal cancer that has specific genetic characteristics known as MSI-H or dMMR. The treatment involves...

Not yet recruiting

Phase: PHASE2 Type: interventional

Related Conditions

Breast Cancer View clinical trials → Stroke View clinical trials → Obesity View clinical trials → Cancer View clinical trials → Prostate Cancer View clinical trials → Healthy View clinical trials →

Search All Trials Browse All Conditions